EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years

Marwan Sabbagh iD, Cristina Boschini, Sharon Cohen, Magnus Fugger, Frank Jessen, Sune Dandanell, Sue D Pedersen, Luis Rafael Solís Tarazona, Vanita R Aroda

Alzheimer's & Dementia: Translational Research & Clinical Interventions · 2025-04 · 11 (2)

DOI: 10.1002/trc2.70076 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia: Translational Research & Clinical Interventions, online erschienen am 06.05.2025. Verfasst von Marwan Sabbagh und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology Barrow Neurological Institute Phoenix Arizona USA. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION The evoke/evoke+ trials are investigating semaglutide in a population with early Alzheimer's disease (AD). Specific analyses of semaglutide safety data in older adults are limited; therefore, in the current analysis, we aimed to evaluate safety considerations with semaglutide in adults ≥ 65 years. METHODS Adverse event (AE) data from three semaglutide phase 3a programs in participants ≥ 65 years with type 2 diabetes and/or overweight/obesity were pooled. Change in body weight was also assessed in a smaller subset of participants ≥ 65 years. RESULTS The analysis included 3529 participants ≥ 65 years. Baseline mean age and body mass index in participants ≥ 65 years were 69.3 to 70.2 years and 29.7 to 35.4 kg/m 2 , respectively, compared to 47.8 to 58.5 years and 31.3 to 36.7 kg/m 2 in the overall population. AEs with semaglutide occurred in 73.6% to 92.4% of participants ≥ 65 years versus 73.2% to 90.8% of the overall population. AEs with semaglutide leading to permanent discontinuation appeared to be more frequent in participants ≥ 65 years (9.3%–12.4%) versus the overall population (5.7%–8.7%). Gastrointestinal disorders were the most frequently reported AEs with semaglutide in participants ≥ 65 years (44.6%–73.8%) and in the overall population (39.1%–73.4%). Participants aged ≥ 65 years receiving semaglutide had an estimated weight loss of 3.8% at week 52 compared to 0.1% with placebo. DISCUSSION Age ≥ 65 years did not appear to affect the safety considerations of semaglutide. The ongoing evoke/evoke+ trials will elucidate the balance of efficacy and safety in the treatment of early AD with semaglutide. Highlights This was a post hoc analysis evaluating adverse event (AE) data of semaglutide in people ≥ 65 years. The most common AE with semaglutide was gastrointestinal (GI). GI event rates were similar in people ≥ 65 years and the overall study populations.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseadverse eventearlyglucagon‐like peptide‐1 analoguepooled analysissafetysemaglutide

Autor:innen und Institutionen

  • Department of Neurology Barrow Neurological Institute Phoenix Arizona USA.
  • Novo Nordisk A/S Bagsværd Denmark.
  • Toronto Memory Program Toronto Ontario Canada.
  • Department of Psychiatry University Hospital of Cologne Cologne Germany.
  • C-endo Diabetes and Endocrinology Clinic Calgary Canada.
  • Brigham and Women's Hospital, Harvard Medical School Boston Massachusetts USA.

ORCID-Profile: Marwan Sabbagh

Zitieren

APA

Sabbagh, M., Boschini, C., Cohen, S., Fugger, M., Jessen, F., Dandanell, S., Pedersen, S. D., Tarazona, L. R. S., & Aroda, V. R. (2025). Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years. Alzheimer's & Dementia: Translational Research & Clinical Interventions, 11(2). https://doi.org/10.1002/trc2.70076

Vancouver

Sabbagh M, Boschini C, Cohen S, Fugger M, Jessen F, Dandanell S, et al. Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years. Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2025;11(2). doi:10.1002/trc2.70076

BibTeX
@article{Sabbagh2025,
  author = {Sabbagh, Marwan and Boschini, Cristina and Cohen, Sharon and Fugger, Magnus and Jessen, Frank and Dandanell, Sune and Pedersen, Sue D and Tarazona, Luis Rafael Solís and Aroda, Vanita R},
  title = {Safety considerations of semaglutide in the potential treatment of Alzheimer's disease: A pooled analysis of semaglutide in adults aged ≥ 65 years},
  journal = {Alzheimer's & Dementia: Translational Research & Clinical Interventions},
  year = {2025},
  volume = {11},
  number = {2},
  doi = {10.1002/trc2.70076}
}
Kostenlos starten →